Kasaie Parastu, Pennington Jeff, Shah Maunank S, Berry Stephen A, German Danielle, Flynn Colin P, Beyrer Chris, Dowdy David W
*Departments of Health, Behavior and Society; †Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD; and §Department of Health and Mental Hygiene (DHMH), Center for HIV Surveillance, Epidemiology and Evaluation, Baltimore, MD.
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):175-183. doi: 10.1097/QAI.0000000000001354.
Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation.
We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage, and use of antiretroviral therapy. We use this framework to compare PrEP delivery strategies in terms of impact on HIV incidence and prevalence.
The projected reduction in HIV incidence achievable with PrEP reflects both population-level coverage and individual-level adherence (as a proportion of days protected against HIV transmission). For example, provision of PrEP to 40% of HIV-negative MSM reporting more than one sexual partner in the last 12 months, taken with sufficient adherence to provide protection on 40% of days, can reduce HIV incidence by 9.5% (95% uncertainty range: 8%-11%) within 5 years. However, if this could be increased to 80% coverage on 80% of days (eg, through mass campaigns with a long-acting injectable formulation), a 43% (42%-44%) reduction in HIV incidence could be achieved. Delivering PrEP to MSM at high risk for HIV acquisition can augment population-level impact up to 1.8-fold.
If highly ambitious targets for coverage and adherence can be achieved, PrEP can substantially reduce HIV incidence in the short-term. Although the reduction in HIV incidence largely reflects the proportion of person-years protected, the efficiency of PrEP delivery can be enhanced by targeting high-risk populations.
暴露前预防(PrEP)被推荐用于预防高危人群感染艾滋病毒,其中包括男男性行为者(MSM)。尽管其个体层面的疗效已得到证实,但关于PrEP实施的人群层面影响仍存在疑问。
我们开发了一个基于主体的男男性行为者艾滋病毒传播模拟模型,该模型考虑了人口统计学、性接触网络、艾滋病毒疾病阶段以及抗逆转录病毒疗法的使用情况。我们使用这个框架来比较PrEP提供策略对艾滋病毒发病率和流行率的影响。
PrEP可实现的预计艾滋病毒发病率降低既反映了人群层面的覆盖率,也反映了个体层面的依从性(作为预防艾滋病毒传播天数的比例)。例如,在过去12个月内报告有多个性伴侣的艾滋病毒阴性男男性行为者中,为40%的人提供PrEP,并确保足够的依从性以在40%的天数内提供保护,可在5年内将艾滋病毒发病率降低9.5%(95%不确定范围:8%-11%)。然而,如果能够将覆盖率提高到80%且在80%的天数内提供保护(例如,通过长效注射制剂的大规模宣传活动),则可将艾滋病毒发病率降低43%(42%-44%)。向艾滋病毒感染高危的男男性行为者提供PrEP可使人群层面的影响增加高达1.8倍。
如果能够实现覆盖率和依从性的高宏伟目标,PrEP可在短期内大幅降低艾滋病毒发病率。尽管艾滋病毒发病率的降低在很大程度上反映了受保护人年的比例,但通过针对高危人群可提高PrEP提供的效率。